F313S (F313S) News

Form 8-K - Current report

CARGO Therapeutics to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a...

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

– Financing includes participation from new and existing investors –  – Supports BLA preparation for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of...

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a...

CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a...

CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a...